دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Population Attributable Risk of Advanced-Stage Breast Cancer by Race and Ethnicity
Karla Kerlikowske, MD1,2; Shuai Chen, PhD3; Michael C. S. Bissell, PhD3,4; Christoph I. Lee, MD5; Jeffrey A. Tice, MD1; Brian L. Sprague, PhD6; Diana L. Miglioretti, PhD3,7
doi : 10.1001/jamaoncol.2023.5242
February 2024, Vol 10, No. 2, Pages 154-264
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer
Naomi Takemura, PhD1; Denise Shuk Ting Cheung, PhD1; Daniel Yee Tak Fong, PhD1; Anne Wing Mui Lee, MD2,3; Tai-Chung Lam, MBBS2,3,4; James Chung-Man Ho, MD5; Tsz Yeung Kam, MBChB6; Jeannie Yin Kwan Chik, MBBS7; Chia-Chin Lin, PhD1,8,9
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Krishnansu S. Tewari, MD1; Nicoletta Colombo, MD, PhD2; Bradley J. Monk, MD3; Coraline Dubot, MD4; M. Valeria Cáceres, MD, PhD5; Kosei Hasegawa, MD, PhD6; Ronnie Shapira-Frommer, MD7; Pamela Salman, MD8; Eduardo Yañez, MD9; Mahmut Gümüş, MD10; Mivael Olivera Hurtado de Mendoza, MD11; Vanessa Samouëlian, MD, PhD12; Vincent Castonguay, MD13; Alexander Arkhipov, MD, PhD14; Cumhur Tekin, MD15; Kan Li, PhD15; Sarper Toker, MD, MBA15; Stephen M. Keefe, MD15; Domenica Lorusso, MD, PhD16
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
Brian D. Lehmann, PhD1,2; Vandana G. Abramson, MD1,2; E. Claire Dees, MD3; Payal D. Shah, MD4; Tarah J. Ballinger, MD5; Claudine Isaacs, MD6; Cesar A. Santa-Maria, MD7; Hanbing An, PhD8; Paula I. Gonzalez-Ericsson, MD2,9; Melinda E. Sanders, MD2,10; Kimberly C. Newsom2; Richard G. Abramson, MD11; Quanhu Sheng, PhD12,13; Chih-Yuan Hsu, PhD12,13; Yu Shyr, PhD12,13; Antonio C. Wolff, MD7; Jennifer A. Pietenpol, PhD2,14
Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes
Sanne-Marije J. A. Hazen, MD1,2,3; Tania C. Sluckin, MD1,2,3; Martijn P. W. Intven, MD, PhD4; Geerard L. Beets, MD, PhD5,6; Regina G. H. Beets-Tan, MD, PhD6,7; Wernard A. A. Borstlap, MD, PhD8; Tineke E. Buffart, MD, PhD2,9; Jeroen Buijsen, MD, PhD10,11; Jacobus W. A. Burger, MD, PhD12; Susan van Dieren, PhD2,13; Edgar J. B. Furnée, MD, PhD14; E. Debby Geijsen, MD2,15; Roel Hompes, MD, PhD2,8; Karin Horsthuis, MD, PhD3,16; Jeroen W. A. Leijtens, MD, PhD17; Monique Maas, MD, PhD7; Jarno Melenhorst, MD, PhD6,18; Joost Nederend, MD, PhD19; Koen C. M. J. Peeters, MD, PhD20; Tom Rozema, MD21; Jurriaan B. Tuynman, MD, PhD1,2,3; Cornelis Verhoef, MD, PhD22; Marianne de Vries, MD, PhD23; Henderik L. van Westreenen, MD, PhD24; Johannes H.W. de Wilt, MD, PhD25; David D. E. Zimmerman, MD, PhD26; Corrie A. M. Marijnen, MD, PhD27,28; Pieter J. Tanis, MD, PhD2,3,8,22; Miranda Kusters, MD, PhD1,2,3; for the Dutch Snapshot Research Group
Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing
Carolyn Horton, MS1; Lily Hoang, BS1; Heather Zimmermann, PhD1; Colin Young, PhD1; Jessica Grzybowski, MS1; Kate Durda, MS1; Huy Vuong, PhD1; David Burks, PhD1; Ashley Cass, PhD1; Holly LaDuca, MS1; Marcy E. Richardson, PhD1; Steven Harrison, PhD1; Elizabeth C. Chao, MD1,2; Rachid Karam, MD, PhD1
Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant
Ruihao Huang, MD1; Ting Chen, MD1; Sanbin Wang, MD2; Jishi Wang, MD3; Yi Su, MD4; Jing Liu, MD5; Yanqi Zhang, PhD6; Xiangyu Ma, PhD7; Qin Wen, MD1; Peiyan Kong, MD1; Cheng Zhang, MD1; Lei Gao, MD1; Jiang F. Zhong, PhD8; Li Gao, MD1; Xi Zhang, MD, PhD1,9
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
Priyanka Sharma, MD1; Shane R. Stecklein, MD, PhD2,3,4; Rachel Yoder, MS5; Joshua M. Staley, MS5; Kelsey Schwensen, BS1; Anne O’Dea, MD1; Lauren Nye, MD1; Deepti Satelli, MD1; Gregory Crane, MD1; Rashna Madan, MBBS3; Maura F. O’Neil, MD3; Jamie Wagner, DO6; Kelsey E. Larson, MD6; Christa Balanoff, MD6; Lyndsey Kilgore, MD6; Milind A. Phadnis, PhD7; Andrew K. Godwin, PhD3,5; Roberto Salgado, MD8,9; Qamar J. Khan, MD1; Joyce O’Shaughnessy, MD10
The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer
Alexandre Bolze, PhD1; Elizabeth T. Cirulli, PhD1; Catherine Hajek, MD1; Jamie M. Schnell Blitstein, DNP2; Joseph J. Grzymski, PhD2,3
GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Lindsey Wang1; William Wang1; David C. Kaelber, MD, MPH, PhD2; Rong Xu, PhD3,4; Nathan A. Berger, MD1,4
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
Alireza Ghoreifi, MD1; Ulka Vaishampayan, MD2; Ming Yin, MD3; Sarah P. Psutka, MD4; Hooman Djaladat, MD1
Rapid Advances in Resectable Non–Small Cell Lung Cancer
Howard (Jack) West, MD, MPhil1,2; Jae Y. Kim, MD3
Addressing the Drug-Shortage Crisis in Oncology
Y. Tony Yang, ScD, LLM, MPH1,2; Mariana Socal, MD, PhD3; Charles L. Bennett, MD, PhD, MPP4
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind�
Justin M. Barnes, MD, MS1; K. Robin Yabroff, PhD2; Fumiko Chino, MD3
The Long Behavioral Tail of the COVID-19 Pandemic—A Cancer Control Perspective
William M. P. Klein, PhD1; Laura A. Dwyer, PhD2; Katrina A. B. Goddard, PhD1
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For
Dionisia Quiroga, DO, PhD1; Margaret E. Gatti-Mays, MD, MPH1
Reflections on My Journey With Cancer—Unexpected Insights From Game Night
Jorge Cortez Campaña, Ing1
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases
Michael Yan, MD, MPH1; Fabio Ynoe Moraes, MD, PhD2
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases
Sezin Yuce Sari, MD1; Nihat Demir, MD1; Gozde Yazici, MD1
Nontumor Cells in Tumor Samples Bias Expression-Based Models
Jiaqi Liang, PhD1; Guoshu Bi, PhD1; Cheng Zhan, PhD1
Nontumor Cells in Tumor Samples Bias Expression-Based Models—Reply
Rohan R. Katipally, MD1; Sean P. Pitroda, MD1
